Abstract
Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.
| Original language | English (US) |
|---|---|
| Journal | British Journal of Cancer |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. / Metcalfe, Kelly; Lynch, Henry T.; Foulkes, William D.; Tung, Nadine; Olopade, Olufunmilayo I.; Eisen, Andrea; Lerner-Ellis, Jordan; Snyder, Carrie; Kim, Shana J.; Sun, Ping; Narod, Steven A.
In: British Journal of Cancer, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oestrogen receptor status and survival in women with BRCA2-associated breast cancer
AU - Metcalfe, Kelly
AU - Lynch, Henry T.
AU - Foulkes, William D.
AU - Tung, Nadine
AU - Olopade, Olufunmilayo I.
AU - Eisen, Andrea
AU - Lerner-Ellis, Jordan
AU - Snyder, Carrie
AU - Kim, Shana J.
AU - Sun, Ping
AU - Narod, Steven A.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.
AB - Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85061179604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061179604&partnerID=8YFLogxK
U2 - 10.1038/s41416-019-0376-y
DO - 10.1038/s41416-019-0376-y
M3 - Article
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
ER -